Oncology & Cancer

Drug can delay ovarian cancer relapses: study

A drug already approved for treating kidney cancer was successful at delaying the return of advanced ovarian cancer by an average of nearly six months, a clinical study released Saturday found.

Oncology & Cancer

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, leucovorin, ...

Oncology & Cancer

Bevacizumab active in HIV-linked Kaposi's sarcoma

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of Clinical Oncology.

Medications

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...

Oncology & Cancer

'Microbeads' may boost survival in advanced colon cancer patients

(HealthDay News) —For advanced colon cancer patients who have developed liver tumors, so-called "radioactive beads" implanted near these tumors may extend survival nearly a year longer than among patients on chemotherapy ...

page 5 from 12